Skip to main content
SpringerLink
Log in

Low-dose Rivaroxaban: is it a safe alternative in Chinese older patients?

  • Research
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

10 mg rivaroxaban is widely used in the Chinese mainland. This study aims to explore the association between 10 mg once daily rivaroxaban and all-cause mortality in patients with nonvalvular atrial fibrillation (NVAF).

Methods

This observational study enrolled 1131 NVAF patients at the cardiovascular department of the First Affiliated Hospital of Xi’an Jiaotong University. One-year outcomes included all-cause mortality and bleeding were recorded. Cox proportional hazards models and Kaplan-Meier analysis were utilized in the study.

Results

In total, 1131 patients (402 no anticoagulants, and 729 rivaroxaban) were included. Cox proportional hazard analysis demonstrated that low-dose rivaroxaban (10 mg, HR: 0.14, 95% CI:(0.07–0.28), P<0.001; 15 mg, HR: 0.20, 95% CI:(0.09–0.43), P<0.001; 20 mg, HR: 0.22, 95% CI:(0.05–0.96), P = 0.044) exhibited lower mortality risk compared to untreated patients.

Conclusions

10 mg once daily rivaroxaban may provide survival benefits for elderly patients with NVAF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

References

  1. Wilkinson C, Todd O, Clegg A et al (2019) Management of atrial fibrillation for older people with frailty: a systematic review and meta-analysis. Age Ageing 48196–48203. https://doi.org/10.1093/ageing/afy180

  2. Soo Y, Chan N, Leung KT et al (2017) Age-specific trends of atrial fibrillation-related ischaemic Stroke and transient ischaemic Attack, anticoagulant use and risk factor profile in Chinese population: a 15-year study. J Neurol Neurosurg Psychiatry 88744–88748. https://doi.org/10.1136/jnnp-2017-315735

  3. Guo Y, Tian Y, Wang H et al (2015) Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest 147109–147119. https://doi.org/10.1378/chest.14-0321

  4. Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365883–365891. https://doi.org/10.1056/NEJMoa1009638

  5. Lane DA, Wood K (2015) Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation. Circulation 131e412-415. https://doi.org/10.1161/CIRCULATIONAHA.114.012808

  6. Lin D, Chen Y, Yong J et al (2021) Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian patients with Atrial Fibrillation? Front Cardiovasc Med 8768730. https://doi.org/10.3389/fcvm.2021.768730

  7. Camm AJ, Cools F, Virdone S et al (2020) Mortality in patients with Atrial Fibrillation receiving nonrecommended doses of direct oral anticoagulants. J Am Coll Cardiol 761425–761436. https://doi.org/10.1016/j.jacc.2020.07.045

  8. Chan YH, Kuo CT, Yeh YH et al (2016) Thromboembolic, bleeding, and mortality risks of Rivaroxaban and Dabigatran in asians with Nonvalvular Atrial Fibrillation. J Am Coll Cardiol 681389–681401. https://doi.org/10.1016/j.jacc.2016.06.062

  9. Ogawa S, Ikeda T, Kitazono T et al (2014) Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation: insights from the Rivaroxaban Postmarketing Surveillance Registry. J Stroke Cerebrovasc Dis 232520–232526. https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.03.006

  10. Chan YH, Lee HF, See LC et al (2019) Effectiveness and safety of four direct oral anticoagulants in Asian patients with Nonvalvular Atrial Fibrillation. Chest 156529:543. https://doi.org/10.1016/j.chest.2019.04.108

    Article  Google Scholar 

  11. Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150604–150612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006

  12. Steffel J, Verhamme P, Potpara TS et al (2018) The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 391330–391393. https://doi.org/10.1093/eurheartj/ehy136

  13. Steinberg BA, Shrader P, Thomas L et al (2016) Off-label dosing of Non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry. J Am Coll Cardiol 682597–682604. https://doi.org/10.1016/j.jacc.2016.09.966

  14. Lee HF, Chan YH, Tu HT et al (2018) The effectiveness and safety of low-dose rivaroxaban in asians with non-valvular atrial fibrillation. Int J Cardiol 26178–26183. https://doi.org/10.1016/j.ijcard.2018.03.063

  15. Yu HT, Yang PS, Jang E et al (2020) Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with Atrial Fibrillation. J Am Heart Assoc. 9e014177 https://doi.org/10.1161/JAHA.119.014177

    Article  PubMed  PubMed Central  Google Scholar 

  16. Qian J, Yan YD, Yang SY et al (2021) Benefits and Harms of Low-Dose Rivaroxaban in Asian patients with Atrial Fibrillation: a systematic review and Meta-analysis of real-World studies. Front Pharmacol 12642907. https://doi.org/10.3389/fphar.2021.642907

  17. Lin YC, Chien SC, Hsieh YC et al (2018) Effectiveness and safety of Standard- and low-dose Rivaroxaban in asians with Atrial Fibrillation. J Am Coll Cardiol 72477–72485. https://doi.org/10.1016/j.jacc.2018.04.084

Download references

Acknowledgements

This work was supported by the Natural Science Foundation of Shaanxi Provincial Department of Education grants (Grant numbers 2016JM8082).

Funding

This work was supported by the Natural Science Foundation of Shaanxi Provincial Department of Education grants (Grant numbers 2016JM8082).

Author information

Author notes

  1. Yue Yu and Wei Yang contributed equally to this work.

Authors and Affiliations

  1. Department of Geriatrics, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061, P.R. China

    Yue Yu, Wei Yang, Dan Luo & Xianming Su

  2. Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061, P.R. China

    Wenyuan Li, Ge Gao & Yue Wu

Authors
  1. Yue Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wenyuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ge Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dan Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yue Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xianming Su
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YY and WY devised the conceptualization and methodology. YY drafted the original manuscript draft. YY, WY, and WYL collected the clinical data. YY and WY performed the data analysis and analysis visualizations. GG, DL, YW, and XMS edited the manuscript. YW and XMS had primary responsibility for final content. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Yue Wu or Xianming Su.

Ethics declarations

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the ethic committee approval of the First Affiliated Hospital of Xi’an Jiaotong University (No. XJTU1AF2023LSK-333). The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

Informed consent

No written informed consent was obtained from patients, as the study used anonymous register data.

Competing interests

The authors declare that the research was conducted without commercial or financial relationships.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, Y., Yang, W., Li, W. et al. Low-dose Rivaroxaban: is it a safe alternative in Chinese older patients?. Eur J Clin Pharmacol 80, 409–415 (2024). https://doi.org/10.1007/s00228-023-03615-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-023-03615-z

Keywords

Search

Navigation